AVEO Oncology
AVEO
$15.00
Share price
0.00%
Change (1 day)
170.76%
Change (1 year)
Categories
Operating Margin for AVEO Oncology (AVEO)
Operating Margin as of April 2024 (TTM): -30.78%
According to AVEO Oncology 's latest financial reports and stock price the company's current Operating Margin is -30.78%. At the end of 2021 the company had an Operating Margin of -126.12%.
Operating Margin history for AVEO Oncology from 2009 to 2022
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2021 | -126.12% | -78.67% |
| 2020 | -591.19% | -1913.32% |
| 2019 | 32.60% | -133.09% |
| 2018 | -98.52% | -88.5% |
| 2017 | -856.63% | -19.57% |
| 2016 | -1,065.05% | 1250.68% |
| 2015 | -78.85% | -72.9% |
| 2014 | -291.01% | -96.48% |
| 2013 | -8,277.57% | 1295.54% |
| 2012 | -593.15% | -3290.4% |
| 2011 | 18.59% | -114.13% |
| 2010 | -131.57% | -38.32% |
| 2009 | -213.30% | 29.14% |
| 2008 | -165.17% | -27.05% |
| 2007 | -226.40% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Eli Lilly LLY | 24.66% | -180.12% | 🇺🇸 USA |
 Amgen AMGN | 34.59% | -212.38% | 🇺🇸 USA |
 Biogen BIIB | 31.30% | -201.69% | 🇺🇸 USA |
 Regeneron Pharmaceuticals REGN | 37.68% | -222.42% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 19.24% | -162.51% | 🇺🇸 USA |
 Merrimack Pharmaceuticals MACK | -106.40% | 245.68% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.